Epidemiological Study of Tricuspid Regurgitation After Cardiac Transplantation. Does it Influence Survival?

• Published in: Transplant international Vol. 35; p. 10197
• Main Authors: López-Vilella, Raquel, Paniagua-Martín, María J, González-Vílchez, Francisco, Donoso Trenado, Víctor, Barge-Caballero, Eduardo, Sánchez-Lázaro, Ignacio, Aller Fernández, Ana V, Martínez-Dolz, Luis, Crespo-Leiro, María G, Almenar-Bonet, Luis
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 21.03.2022
• Subjects: Health Archive; Heart Transplantation - adverse effects; Humans; Incidence; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Tricuspid Valve Insufficiency - complications; Tricuspid Valve Insufficiency - etiology; aetiology; tricuspid regurgitation; heart transplantation; prognosis; survival
• ISSN: 1432-2277; 0934-0874; 1432-2277
• DOI: 10.3389/ti.2022.10197

Tricuspid valve disease is the most frequent valvulopathy after heart transplantation (HTx). Evidence for the negative effect of post-transplant tricuspid regurgitation (TR) on survival is contradictory. The aim of this study was to analyze the causes of post-transplant TR and its effect on overall mortality. This is a retrospective observational study of all transplants performed in two Spanish centers (1009 patients) between 2000 and 2019. Of the total number of patients, 809 had no TR or mild TR and 200 had moderate or severe TR. The etiology of TR was analyzed in all cases. The prevalence of moderate and severe TR was 19.8%. The risk of mortality was greater when TR was caused by early primary graft failure (PGF) or rejection ( < 0.05). TR incidence was related to etiology: incidence of PGF-induced TR was higher in the first period, while TR due to rejection and undefined causes occurred more frequently in three periods: in the first year, in the 10-14-year period following HTx, and in the long term (16-18 years). In the multivariable analysis, TR was significantly associated with mortality/retransplantation (HR:1.04, 95% CI:1.01-1.07, p:0.02). The development of TR after HTx is relatively frequent. The annual incidence depends on TR severity and etiology. The risk of mortality is greater in severe TR due to PGF or rejection.